LI

aTyr Pharma

- NASDAQ:LIFE
Last Updated 2024-03-26

LinkedIn Profile

Access aTyr Pharma historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:life 109867 Mar 23rd, 2024 12:00AM aTyr Pharma 5.2K 75.00 Open Mar 22nd, 2024 11:50PM Mar 23rd, 2024 07:00PM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 22nd, 2024 12:00AM aTyr Pharma 5.2K 75.00 Open Mar 21st, 2024 11:41PM Mar 22nd, 2024 06:48PM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 21st, 2024 12:00AM aTyr Pharma 5.2K 74.00 Open Mar 20th, 2024 11:54PM Mar 21st, 2024 05:32PM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 20th, 2024 12:00AM aTyr Pharma 5.2K 74.00 Open Mar 20th, 2024 12:31AM Mar 20th, 2024 07:33PM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 19th, 2024 12:00AM aTyr Pharma 5.2K 74.00 Open Mar 18th, 2024 11:29PM Mar 19th, 2024 06:05PM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 18th, 2024 12:00AM aTyr Pharma 5.2K 74.00 Open Mar 17th, 2024 11:51PM Mar 18th, 2024 07:17PM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 17th, 2024 12:00AM aTyr Pharma 5.2K 74.00 Open Mar 17th, 2024 01:31AM Mar 17th, 2024 01:31AM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 16th, 2024 12:00AM aTyr Pharma 5.2K 74.00 Open Mar 15th, 2024 11:20PM Mar 16th, 2024 07:04PM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 15th, 2024 12:00AM aTyr Pharma 5.2K 74.00 Open Mar 15th, 2024 12:47AM Mar 15th, 2024 08:54AM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology
nasdaq:life 109867 Mar 14th, 2024 12:00AM aTyr Pharma 5.2K 74.00 Open Mar 13th, 2024 11:18PM Mar 14th, 2024 12:15PM aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Open Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases Open 10240 Sorrento Valley Rd San Diego California US 92121 aTyr Pharma Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.